Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy

The primary objective of this study is to investigate whether two weeks of metformin treatment can activate the tumour microenvironment in patients with stage II and III oesophageal adenocarcinomas.

Trial Details

NCT ID
NCT06687876
Phase
PHASE2
Sponsor
Amsterdam UMC, location VUmc
Status
RECRUITING
Cancer Type
Adenocarcinoma Esophageal Cancer
Interventions
  • Metformin
Locations (sample)
  • Amsterdam, Netherlands|52.37403,4.88969
  • Amsterdam, Netherlands|52.37403,4.88969

Key Eligibility Criteria

  • Surgical resectable (\<T4b, N0 or N+, M0), and histologically proven adenocarcinoma of the oesophagus or gastro-oesophageal junction planning to un…
  • Adult patients (age ≥ 18 years).
  • ECOG performance status 0 or 1 (cf. Appendix A).
  • Adequate hematological, renal and hepatic functions defined as:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Esophageal Cancer Trials on Trialify →